What you need to know about the latest FDA ruling on drugs
The U.S. Food and Drug Administration has ruled that a number of generics made by a pharmaceutical company may no longer be labeled as “pharmaceuticals” in the United States, and that other generics may no long be required to list on the label.
The FDA’s decision comes amid widespread outrage over the way pharmaceutical companies are labeling products that have long been used as treatments for the diseases they were created to treat.
The agency is expected to issue a final rule in the coming weeks.
A number of drugs sold by the makers of Johnson & Johnson, Pfizer, and McKesson, as well as others like Humira and Nexium, were listed in the FDA’s database as “other” before they were pulled from the market.
The list was made public by the agency after the FDA filed a petition with Congress in June to make the list public.
The move has caused a stir among consumers who want to know whether they can trust the drugs they buy from the manufacturers.
The decision is an example of how the FDA is trying to get to the bottom of the problem of generic drug makers mislabelling their products.
Some critics, including some medical experts, have called the FDA a tool for pharmaceutical companies to push through their own products.
The ruling, which is in line with other FDA rulings, comes after years of public criticism over how drug makers are labeling their drugs.
The pharmaceutical industry has been trying to push its products through the FDA since the drug maker began doing so in the 1990s, when it introduced a program called the Prescription Drug Marketing Program (PDMP).
The PDMP program has helped drug makers such as Johnson &s; Johnson &am; Co., Pfizer and McKessons sell their products to consumers through a network of pharmacies.
The programs are intended to give consumers access to drugs that are less expensive than generic drugs and less expensive generics.
But critics say the program is not designed to give patients access to cheaper generic drugs.
“Pharmaceutical companies are pushing their own brand of generic drugs, and if you ask patients how it’s possible that they’re seeing so many drugs that aren’t ‘medicines,’ you’ll get the same answer: They’re not doctors’ drugs,” said Paul Siegel, director of the Drug Policy Alliance.
In April, the drug makers withdrew their request for the PDMP to be made public. “
In effect, the FDA has made it clear that it’s OK to continue selling these drugs, without regard to whether they’re good or bad, safe or unsafe,” Siegel said.
In April, the drug makers withdrew their request for the PDMP to be made public.
Johnson & Johnson and Pfizer are the only two companies listed on the FDA database as having withdrawn their applications for inclusion in the new database.
The other three are Humira, AbbVie and GlaxoSmithKline.
The drug companies said in a statement that they are confident that the new list will protect the public and their patients, but noted that they continue to vigorously oppose attempts to change the PDMPs classification.
“We believe this new system will allow for greater transparency and better accountability for the industry’s marketing practices,” the companies said.
“By moving forward, we hope to encourage other companies to take similar steps to ensure that their medicines are labeled in a way that makes clear the differences between the two systems.”